Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib - The role of extracellular signal-regulated kinase counteraction

FEBS Journal

Volumn 278, Issue 18, 2011, Pages 3494-3507

  Manov, Irena ^a   Pollak, Yulia ^a   Broneshter, Rinata ^a   Iancu, Theodore C ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

autophagy; doxorubicin; extracellular signal regulated kinase; hepatocellular carcinoma; sorafenib

Indexed keywords

CYCLIN D1; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; PROTEIN KINASE B; SORAFENIB;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL CYCLE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; DOXORUBICIN; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA, LIVER; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES;

EID: 80052511885     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08271.x     Document Type: Article

References (61)

1. Llovet JM, &, Bruix J, (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (Suppl 1), S20-S37.
2. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, et al. (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97, 1532-1538.
3. Fabregat I, (2009) Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 15, 513-520.
4. Pang RW, &, Poon RT, (2007) From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72 (Suppl 1), 30-44.
5. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, &, Tran E, (2003) Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 8, 3-19.
6. Montagut C, &, Settleman J, (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283, 125-134.
7. Wiesenauer CA, Yip-Schneider MT, Wang Y, &, Schmidt CM, (2004) Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 198, 410-421.
8. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, &, Lynch M, (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7, 3129-3140.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390.
10. Takimoto CH, &, Awada A, (2008) Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61, 535-548.
11. Cabibbo G, Latteri F, Antonucci M, &, Craxi A, (2009) Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 6, 159-169.
12. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, &, Saltz LB, (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304, 2154-2160.
13. Richly H, Schultheis B, Adamietz IA, Kupsch P, Grubert M, Hilger RA, Ludwig M, Brendel E, Christensen O, &, Strumberg D, (2009) Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 45, 579-587.
14. Cagnol S, &, Chambard JC, (2010) ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 277, 2-21.
15. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867.
16. Zhuang S, &, Schnellmann RG, (2006) A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319, 991-997.
17. Lee ER, Kim JY, Kang YJ, Ahn JY, Kim JH, Kim BW, Choi HY, Jeong MY, &, Cho SG, (2006) Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta 1763, 958-968.
18. Manov I, Bashenko Y, Eliaz-Wolkowicz A, Mizrahi M, Liran O, &, Iancu TC, (2007) High-dose acetaminophen inhibits the lethal effect of doxorubicin in HepG2 cells: the role of P-glycoprotein and mitogen-activated protein kinase p44/42 pathway. J Pharmacol Exp Ther 322, 1013-1022.
19. Liu J, Mao W, Ding B, &, Liang CS, (2008) ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 295, H1956-H1965.
20. Sivaprasad U, &, Basu A, (2008) Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-alpha-induced cell death in MCF-7 cells. J Cell Mol Med 12, 1265-1271.
21. Wei G, Wang M, Hyslop T, Wang Z, &, Carr BI, (2009) Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer 127, 2949-2958.
22. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, &, Carter C, (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66, 11851-11858.
23. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23, 965-972.
24. Gewirtz DA, (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57, 727-741.
25. Yao Z, Dolginov Y, Hanoch T, Yung Y, Ridner G, Lando Z, Zharhary D, &, Seger R, (2000) Detection of partially phosphorylated forms of ERK by monoclonal antibodies reveals spatial regulation of ERK activity by phosphatases. FEBS Lett 468, 37-42.
26. Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, &, Schmidt CM, (2009) Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther 329, 1063-1070.
27. Eskelinen EL, (2005) Maturation of autophagic vacuoles in mammalian cells. Autophagy 1, 1-10.
28. Huynh H, Do PT, Nguyen TH, Chow P, Tan PH, Quach TH, Van T, Soo KC, &, Tran E, (2004) Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. Int J Oncol 25, 1839-1847.
29. Stacey DW, (2003) Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 15, 158-163.
30. Alao JP, (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6, 1-16.
31. Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D'Amelio M, Djavaheri-Mergny M, Cecconi F, Tavernarakis N, &, Kroemer G, (2008) A dual role of p53 in the control of autophagy. Autophagy 4, 810-814.
32. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773, 1263-1284.
33. Balmanno K, &, Cook SJ, (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16, 368-377.
34. Lu Y, &, Cederbaum A, (2007) The mode of cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells: modulation by ERK, ROS, glutathione, and thioredoxin. Free Radic Biol Med 43, 1061-1075.
35. Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun HJ, &, Fayyazi A, (2004) Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br J Cancer 91, 589-598.
36. Small GW, Somasundaram S, Moore DT, Shi YY, &, Orlowski RZ, (2003) Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 307, 861-869.
37. Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, &, Chu CT, (2007) Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol 170, 75-86.
38. Gozuacik D, &, Kimchi A, (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23, 2891-2906.
39. Corcelle EA, Puustinen P, &, Jaattela M, (2009) Apoptosis and autophagy: targeting autophagy signalling in cancer cells -'trick or treats'? FEBS J 276, 6084-6096.
40. Dalby KN, Tekedereli I, Lopez-Berestein G, &, Ozpolat B, (2010) Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6, 322-329.
41. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, &, Tsujimoto Y, (2004) Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 6, 1221-1228.
42. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273, 18623-18632.
43. Fremin C, &, Meloche S, (2010) From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 3:8, 1-16.
44. Kamakura S, Moriguchi T, &, Nishida E, (1999) Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274, 26563-26571.
45. Pipaon C, Gutierrez P, Montero JC, Lorenzo M, Eguiraun A, De la Fuente JA, Pandiella A, Leon J, &, Ortiz JM, (2002) Mitogen-activated protein kinase routes as targets in the action of diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells. Mol Cancer Ther 1, 811-819.
46. Poizat C, Puri PL, Bai Y, &, Kedes L, (2005) Phosphorylation- dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Mol Cell Biol 25, 2673-2687.
47. Vogt A, Adachi T, Ducruet AP, Chesebrough J, Nemoto K, Carr BI, &, Lazo JS, (2001) Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases. J Biol Chem 276, 20544-20550.
48. Kobayashi S, Volden P, Timm D, Mao K, Xu X, &, Liang Q, (2010) Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem 285, 793-804.
49. Corcelle E, Nebout M, Bekri S, Gauthier N, Hofman P, Poujeol P, Fenichel P, &, Mograbi B, (2006) Disruption of autophagy at the maturation step by the carcinogen lindane is associated with the sustained mitogen-activated protein kinase/extracellular signal-regulated kinase activity. Cancer Res 66, 6861-6870.
50. He M, Zhao M, Shen B, Prise KM, &, Shao C, (2010) Radiation-induced intercellular signaling mediated by cytochrome-c via a p53-dependent pathway in hepatoma cells. Oncogene 285, 793-804.
51. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, &, Vali M, (2010) 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res 30, 923-935.
52. French KJ, Coatney RW, Renninger JP, Hu CX, Gales TL, Zhao S, Storck LM, Davis CB, McSurdy-Freed J, Chen E, et al. (2010) Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. Toxicol Pathol 38, 691-702.
53. Fasanaro P, Magenta A, Zaccagnini G, Cicchillitti L, Fucile S, Eusebi F, Biglioli P, Capogrossi MC, &, Martelli F, (2006) Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress. FASEB J 20, 1242-1244.
54. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, &, Adjei AA, (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861-6869.
55. Kitazumi I, &, Tsukahara M, (2010) Regulation of DNA fragmentation: the role of caspases and phosphorylation. FEBS J 278, 427-441.
56. Cheng C, &, Zochodne DW, (2003) Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 52, 2363-2371.
57. Levine B, &, Yuan J, (2005) Autophagy in cell death: an innocent convict? J Clin Invest 115, 2679-2688.
58. Honma N, Genda T, Matsuda Y, Yamagiwa S, Takamura M, Ichida T, &, Aoyagi Y, (2006) MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. Lab Invest 86, 687-696.
59. Hutchinson L, (2011) Targeted therapies: doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma. Nat Rev Clin Oncol 8, 61.
60. Manov I, Hirsh M, &, Iancu TC, (2002) Acetaminophen hepatotoxicity and mechanisms of its protection by N-acetylcysteine: a study of Hep3B cells. Exp Toxicol Pathol 53, 489-500.
61. Manov I, Bashenko Y, Hirsh M, &, Iancu TC, (2006) Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells. Basic Clin Pharmacol Toxicol 99, 213-224.